Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs DigitalOcean Holdings Inc (DOCN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs DigitalOcean Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.29 (market cap $29.60B), while DigitalOcean Holdings Inc trades at $133.08 (market cap $14.21B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.1× DigitalOcean Holdings Inc's market cap, and DigitalOcean Holdings Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DOCN | |
|---|---|---|
Market Cap | $29.60B | $14.21B |
Sector | Health | Technology |
52-Week High | $491.22 | $181.29 |
52-Week Low | $205.48 | $29.99 |
Enterprise Value | $27.56B | $14.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
DigitalOcean (DOCN) trades at $133.03, up 2.54% today, with a bearish technical signal but strong fundamental momentum. Recent Q2 2026 earnings beat expectations with 29% revenue growth, driven by AI-native cloud demand. The stock shows high valuation ratios (P/E 54.94, P/S 13.62) and robust profitability (net margin 23.27%, ROE 62.27%). Analyst consensus is bullish with a $173.71 price target, though technical indicators suggest near-term resistance at $134.
Outlook is positive due to accelerating AI-driven growth and raised 2027 guidance, but risks include high debt levels and valuation concerns. The stock offers upside if execution continues, yet volatility near resistance may prompt consolidation. Investors should weigh strong earnings against technical bearishness and leverage exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →
